PMID- 27257940
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20181202
IS  - 1473-6322 (Electronic)
IS  - 1473-6322 (Linking)
VI  - 16
IP  - 4
DP  - 2016 Aug
TI  - Development of nanostructures in the diagnosis of drug hypersensitivity 
      reactions.
PG  - 300-7
LID - 10.1097/ACI.0000000000000282 [doi]
AB  - PURPOSE OF REVIEW: This article provides an overview of novel nanoscale 
      structures potentially applicable to the field of allergy, and to discuss the 
      required properties, advantages, and disadvantages of those nanostructures for 
      clinical application focusing on diagnosis of drug hypersensitivity reactions. 
      RECENT FINDINGS: Advances in the development of different nanostructures are 
      favoring their biomedical applications. One area of interest is the interaction 
      between nanostructures and the immune system, including their ability to emulate 
      carrier molecules and their potential use for the diagnosis of allergic 
      reactions. SUMMARY: Immunoassays are the most widely used in-vitro test for 
      evaluating immunoglobulin E (IgE)-mediated drug hypersensitivity reactions. 
      However, they have important technical limitations affecting their sensitivity. A 
      wide variety of nanostructures have been designed to quantify specific IgE, with 
      the aim of diagnosing different kinds of allergies. Nanoparticles-based colloidal 
      immunoassay employed in microdevices and/or miniaturized systems are improving 
      IgE detection sensitivity. Dendrimers have shown immense potential for the design 
      and development of sensor platforms for evaluating IgE-mediated drug 
      hypersensitivity reactions, due to the increase in hapten density and IgE 
      accessibility. In this sense, a variety of dendritic structures as well as their 
      hybridization to different solid supports have been shown to be successful when 
      applied in the diagnosis of drug allergy. Moreover, the knowledge of the complete 
      antigenic determinants would allow their inclusion and therefore further 
      improvement of the sensitivity.
FAU - Mayorga, Cristobalina
AU  - Mayorga C
AD  - aResearch Laboratory-Allergy Unit, IBIMA-Regional University Hospital of Malaga 
      UMA bDepartment of Organic Chemistry, IBIMA, University of Malaga 
      cBIONAND-Andalusian Centre for Nanomedicine and Biotechnology, Parque Tecnologico 
      de Andalucia, Malaga, Spain.
FAU - Perez-Inestrosa, Ezequiel
AU  - Perez-Inestrosa E
FAU - Molina, Noemi
AU  - Molina N
FAU - Montanez, Maria I
AU  - Montanez MI
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Allergy Clin Immunol
JT  - Current opinion in allergy and clinical immunology
JID - 100936359
RN  - 0 (Allergens)
RN  - 0 (Epitopes)
RN  - 0 (Haptens)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Allergens/immunology/metabolism
MH  - Animals
MH  - Drug Hypersensitivity/*diagnosis
MH  - Epitopes/immunology/metabolism
MH  - Haptens/immunology/metabolism
MH  - Humans
MH  - Immunoassay/methods/*trends
MH  - Immunoglobulin E/metabolism
MH  - Miniaturization
MH  - Nanoparticles/*statistics & numerical data
MH  - Nanostructures/*statistics & numerical data
MH  - Sensitivity and Specificity
EDAT- 2016/06/04 06:00
MHDA- 2017/09/16 06:00
CRDT- 2016/06/04 06:00
PHST- 2016/06/04 06:00 [entrez]
PHST- 2016/06/04 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
AID - 10.1097/ACI.0000000000000282 [doi]
PST - ppublish
SO  - Curr Opin Allergy Clin Immunol. 2016 Aug;16(4):300-7. doi: 
      10.1097/ACI.0000000000000282.